

# Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A

NCT06802055

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Peking Union Medical College Hospital
<b>Enrollment</b>	40 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- Age  $\geq$  18 years;
- Diagnosed with acquired aplastic anemia (AA), excluding congenital AA;
- At least one of the following criteria met at enrollment: hemoglobin  $<$  100 g/L, platelets  $<$  50  $\times$  10<sup>9</sup>/L, or neutrophils  $<$  1.0  $\times$  10<sup>9</sup>/L;
- At enrollment, meeting at least one of the following conditions:
- Cyclosporine A (CsA) ineffective: (CsA) used for at least 3 months without achieving partial response (PR), or disease relapse occurred;
- ... and 5 more (see full listing online)

### Exclusion (12)

- Pancytopenia caused by other reasons, such as myelodysplastic syndrome (MDS);
- Evidence of clonal hematopoietic system bone marrow diseases (e.g., MDS or acute myeloid leukemia, AML);
- Paroxysmal nocturnal hemoglobinuria (PNH) clone  $\geq$  50%;
- History of hematopoietic stem cell transplantation (HSCT) before enrollment;
- Previous use of sirolimus or allergy to sirolimus;
- ... and 7 more (see full listing online)

## Locations (1 total)

---

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China